Is $ADHD worth betting on?

The Alcobra (ADHD) article in Seeking Alpha broadly says that though Alcobra is a company with a failed drug and no future prospects, it has a lot of cash and is selling below its NCAV or net current asset value. 

Read our full take in our SeekingAlpha Marketplace Daily Pharma Scoop.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *